Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences

Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that
members of Transgenea??s management and scientific team have been invited to participate at upcoming (virtual) scientific conferences:

ESMO Targeted Anticancer Therapies Congress 2021 which will take place March 2-4:

A?ric QuA©mA©neur, Executive Vice President and Chief Scientific Officer (CSO), will be speaking in the session 'Where next with Oncolytics'
about Antibody armed oncolytic viruses (ID 42)

Date & Time: March 3rd at 4.20pm (CET)

Royal Society Meeting on 'Immuno-oncology: How to get the immune system to beat cancer' which will take place March 24-25:

This Royal Society meeting will explore immuno-oncology therapies - both current and recent technologies. Eric QuA©mA©neur will participate in the immuno-oncology breakthroughs session.

Date & Time: March 24th at 3.50pm (GMT)

4th Annual European Neoantigen Summit which will take place April 20-22:

Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines, will be speaking about TG4050: Viral immunotherapy meets AI technology

Date & Time: April 22nd at 1pm (CET)

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgenea??s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Companya??s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IOa?? platform).

With Transgenea??s myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »